Last checked at 
LONDON (Alliance News) - GlaxoSmithKline PLC on Tuesday said it received positive results from studies carried out on its Advair Diskus asthma treatment and on its Shingrix treatment for shingles.
However, the FTSE 100-listed drugmaker said that an interim review of data for the first part of its losmapimod phase III study in acute coronary syndrome did not indicate efficacy against its primary endpoint, and did not support investment in the larger second part of the study as it is currently designed.
The company said it will assess the finds of the losmapimod study over the next few months to evaluate all options for future development.
Glaxo said its LABA safety study on Advair Diskus showed a safety level equivalent to fluticasone propionate monotherapy in treating adolescent and adult patients with asthma. Advair Diskus uses a combination of fluticasone propionate and salmeterol.
In addition, Glaxo said a study carried out on Shingrix showed the treatment hit its primary endpoint of achieving 90% efficacy in treating patients aged over 70 with shingles.
The company intends to file a regulatory application for Shingrix for preventing shingles in people aged 50 and over in North America, Japan and the European Union in the second half of 2016.
Glaxo shares were down 0.2% to 1,366.50 pence on Tuesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance and Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
